Organic compounds -- part of the class 532-570 series – Organic compounds – Four or more ring nitrogens in the bicyclo ring system
Patent
1999-01-19
2000-09-26
Gerstl, Robert
Organic compounds -- part of the class 532-570 series
Organic compounds
Four or more ring nitrogens in the bicyclo ring system
544238, C07D47104, A61K 31497
Patent
active
061244562
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates to a novel pyrazolopyridine compound and a salt thereof which are useful as medicaments.
BACKGROUND ART
Some pyrazolopyridine compounds to be useful as psychostimulant, remedy for renal failure, or the like are known (e.g. EP-0299209, EP-0379979, etc.).
DISCLOSURE OF THE INVENTION
The present invention relates to a novel pyrazolopyridine compound and a salt thereof useful as medicaments; processes for the preparation of said pyrazolopyridine compound and a salt thereof; a pharmaceutical composition comprising, as an active ingredient, said pyrazolopyridine compound or a pharmaceutically acceptable salt thereof; a use of said pyrazolopyridine compound or a pharmaceutically acceptable salt thereof as a medicament; and a method for using said pyrazolopyridine compound or a pharmaceutically acceptable salt thereof for therapeutic purposes, which comprises administering said pyrazolopyridine compound or pharmaceutically acceptable salt thereof to a human being or an animal.
The pyrazolopyridine compound and a salt thereof are adenosine antagonists (especially, A.sub.1 receptor antagonist) and possess various pharmacological actions such as cognitive enhancing action, analgesic action, locomotor action, antidepressant action, diuretic action, cardioprotective effect, cardiotonic action, vasodilating action (e.g. cerebral vasodilating action, etc.), the action of increasing the renal blood flow, renal protective effect, improvement action of renal function, enhancing action of lipolysis, inhibition action of anaphylactic bronchoconstriction, acceleration action of the insulin release, the action of increasing the production of erythropoietin, inhibiting action of platelet aggregation, or the like.
They are useful as cognitive enhancer, antidementia drug, psychostimulant, analgesic, cardioprotective agent, antidepressant, ameliorants of cerebral circulation, tranquilizer, drug for heart failure, cardiotonic agent, anti-hypertensive agent, drug for renal failure (renal insufficiency), drug for renal toxicity, renal protective agent, drug for improvement of renal function, diuretic, drug for edema, anti-obesity, antiasthmatic, bronchodilator, drug for apnea, drug for gout, drug for hyperuricemia, drug for sudden infant death syndrome (SIDS), ameliorants of immunosuppressive action of adenosine, antidiabetic agent, drug for ulcer, drug for pancreatitis, drug for Meniere's syndrome, drug for anemia; drug for thrombosis, drug for myocardial infarction, drug for obstruction, drug for arteriosclerosis obliterans, drug for thrombophlebitis, drug for cerebral infarction, drug for transient ischemic attack, drug for angina pectoris, or the like; and useful for the prevention and/or treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, etc.), anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure; hypertension (e.g. essential hypertension, nephrogenous hypertension, etc.); circulatory insufficiency (acute circulatory insufficiency) caused by, for example, ischemia/reperfusion injury (e.g. myocardial ischemia/reperfusion injury, cerebral ischemia/reperfusion injury, peripheral ischemia/reperfusion injury, etc.), shock (e.g. endotoxin shock, hemorrhagic shock, etc.), surgical procedures or the like; post-resuscitation asystole; bradyarrhythmia; electromechanical dissociation; hemodynamic collapse; SIRS (systemic inflammatory response syndrome); multiple organ failure; renal failure (renal insufficiency) (e.g. acute renal failure, etc.), renal toxicity [e.g. renal toxicity induced by a drug such as cisplatins, gentamicin, FR-900506 (disclosed in EP-0184162), cyclosporin (e.g. cyclosporin A) or the like; glycerol, etc.], nephrosis, nephritis, edema (e.g. cardiac edema, nephrotic edema, hepatic edema, idiopathic edema, drug edema, acute angioneurotic edema, hereditary angioneurotic edema, carcinomatous ascites, gestational edema, etc.); obesity, bronchial asthma, gout, hyperuricemia, sudden infant d
REFERENCES:
patent: 4925849 (1990-05-01), Shiokawa et al.
patent: 4994453 (1991-02-01), Shiokawa et al.
patent: 5087629 (1992-02-01), Shiokawa et al.
patent: 5102869 (1992-04-01), Shiokawa et al.
patent: 5102878 (1992-04-01), Shiokawa et al.
patent: 5155114 (1992-10-01), Shiokawa et al.
patent: 5179103 (1993-01-01), Shiokawa et al.
patent: 5204346 (1993-04-01), Shiokawa et al.
patent: 5234930 (1993-08-01), Shiokawa et al.
patent: 5296490 (1994-03-01), Shiokawa et al.
patent: 5338743 (1994-08-01), Shiokawa et al.
patent: 5773530 (1998-06-01), Akahane et al.
Akahane Atsushi
Itani Hiromichi
Kuroda Satoru
Shimizu Yasuyo
Fujisawa Pharmaceutical Co. Ltd.
Gerstl Robert
LandOfFree
Pyrazolopyridine compound and pharmaceutical use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazolopyridine compound and pharmaceutical use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolopyridine compound and pharmaceutical use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2101249